Our Pricing

Mounjaro Or Ozempic Side Effects: What To Expect

Published on: June 03, 2026

Understanding mounjaro or ozempic side effects UK is essential before starting either GLP-1 medication. Both tirzepatide (Mounjaro) and semaglutide (Ozempic) share common gastrointestinal effects, but their dual versus single receptor mechanisms produce distinct side effect profiles that UK prescribers consider when tailoring treatment to individual patients.

Common Side Effects: Mounjaro Or Ozempic Comparison

Both Mounjaro and Ozempic act on the GLP-1 receptor pathway, which explains why they share similar gastrointestinal side effects. In the SURPASS-1 trial, 73% of Mounjaro patients experienced at least one gastrointestinal event, compared with 68% in the STEP-1 trial for semaglutide [1][2]. The most frequently reported effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort.

Nausea represents the most common side effect for both medications, typically peaking during dose escalation phases. Clinical data shows nausea affects approximately 30-44% of Mounjaro users and 20-44% of Ozempic users, with severity generally classified as mild to moderate [1][2]. Most patients report improvement within 4-8 weeks as their body adapts to treatment.

Diarrhoea occurs in approximately 23-30% of patients on either medication, whilst constipation affects 15-24% of users [1][2]. These opposing gastrointestinal effects reflect individual variation in how the GLP-1 pathway influences gut motility. UK prescribers typically recommend dietary adjustments and adequate hydration to manage these symptoms effectively.

Mounjaro-Specific Side Effects From Dual Receptor Action

Mounjaro's unique dual GIP/GLP-1 receptor mechanism produces some distinct side effect patterns not observed with single-pathway medications. The additional GIP receptor activation may contribute to slightly higher rates of injection site reactions, reported in approximately 8-12% of patients compared to 5-8% with semaglutide-only treatments [1].

Fatigue and decreased appetite appear more pronounced with tirzepatide, particularly during the initial 12 weeks of treatment. In SURPASS trials, approximately 11% of patients reported fatigue compared to 5-7% in comparable semaglutide studies [1][3]. This likely reflects the medication's potent effect on appetite-regulating pathways through dual receptor engagement.

Hypoglycaemia risk remains low when Mounjaro is used as monotherapy for weight management, occurring in fewer than 2% of patients [1]. However, UK prescribers exercise caution when combining tirzepatide with other glucose-lowering medications, as dual receptor activation may amplify blood sugar reduction.

Managing Mounjaro-Specific Effects

Our clinical team at Cured Pharmacy recommends starting with the lowest licensed dose (2.5mg weekly) and following the gradual escalation schedule approved by the MHRA. This approach minimises side effect intensity whilst allowing your body to adapt to the dual receptor mechanism. Patients should maintain a symptom diary during the first 8 weeks to help their UK prescriber optimise dosing intervals if needed.

Ozempic-Specific Side Effects And Safety Profile

Ozempic (semaglutide) demonstrates a well-established safety profile from extensive clinical use in both diabetes management and weight loss. The STEP trial programme showed gastrointestinal side effects typically emerge within 4-8 weeks of dose increases, with most resolving spontaneously as treatment continues [2].

Gallbladder-related events, including cholelithiasis and cholecystitis, occurred in approximately 1.6% of semaglutide users in extended trials compared to 0.7% with placebo [2]. UK prescribers typically screen for gallbladder history before initiating treatment and advise patients to report right upper abdominal pain promptly.

Changes in heart rate represent another monitored parameter with semaglutide. Clinical trials documented average heart rate increases of 1-4 beats per minute, which remain within normal physiological ranges for most patients [2]. Those with pre-existing cardiovascular conditions receive particularly careful assessment before starting Ozempic through our UK prescriber consultation process.

Rare But Serious Side Effects: What UK Patients Should Know

Both medications carry MHRA warnings regarding rare but serious adverse events that require immediate medical attention. Acute pancreatitis, whilst uncommon (affecting fewer than 0.2% of patients), presents with severe persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting [1][2]. Patients experiencing these symptoms should discontinue treatment and seek urgent medical assessment.

Thyroid C-cell tumours emerged in rodent studies at exposures significantly higher than therapeutic human doses, leading to a contraindication in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2]. UK prescribers routinely screen for these conditions during the clinical assessment before prescribing either medication.

Severe allergic reactions, including anaphylaxis and angioedema, occur rarely but require immediate emergency treatment. Signs include difficulty breathing, severe rash, swelling of face or throat, and rapid heartbeat [1][2]. Our clinical team ensures all patients understand these warning signs before starting treatment with either Mounjaro or Ozempic.

When To Contact Your Prescriber Urgently

Superintendent pharmacist Tarun Kumar (GPhC 2233073) advises patients to contact their UK prescriber immediately if they experience persistent severe abdominal pain, visual changes, signs of severe dehydration (dark urine, dizziness, reduced urination), or symptoms of gallbladder disease. Early intervention significantly improves outcomes for rare complications whilst maintaining the safety profile that makes these medications suitable for most patients.

Practical Strategies To Minimise Mounjaro Or Ozempic Side Effects

Evidence-based approaches can substantially reduce side effect severity for both medications. Eating smaller, more frequent meals rather than three large meals helps manage nausea and reduces gastric distension. UK patients report better tolerance when avoiding high-fat, spicy, or heavily processed foods during the first 8-12 weeks of treatment [3].

Timing your injection consistently each week, preferably in the evening after your main meal, may reduce next-day nausea for some patients. Staying well-hydrated (aiming for 2-3 litres of water daily) helps prevent constipation and supports the medication's metabolic effects. Ginger tea, peppermint, and small amounts of protein-rich foods can ease nausea without interfering with the medication's efficacy [3].

The dose escalation schedule exists specifically to minimise side effects whilst optimising therapeutic response. Never skip doses or accelerate your titration schedule without consulting your UK prescriber, as this significantly increases gastrointestinal side effect risk. Most patients achieve their maintenance dose within 16-20 weeks, at which point side effects typically stabilise or resolve entirely [1][2].

Dietary Modifications That Help

Focus on lean proteins, complex carbohydrates, and fibre-rich vegetables whilst limiting simple sugars and saturated fats. This eating pattern naturally complements how GLP-1 medications regulate appetite and blood sugar. Patients following these dietary principles alongside their prescribed medication report fewer gastrointestinal symptoms and achieve better weight loss outcomes in clinical practice.

Choosing Between Mounjaro And Ozempic Based On Side Effect Tolerance

Individual side effect tolerance varies considerably, making personalised prescriber assessment essential. Patients with sensitive stomachs or previous gastrointestinal conditions may benefit from starting with lower doses and slower titration schedules. UK prescribers consider your complete medical history, current medications, and lifestyle factors when recommending either tirzepatide or semaglutide.

Mounjaro's dual receptor mechanism produces greater average weight loss (up to 22.5% body weight in SURPASS-3 versus 14.9% in STEP-1 for semaglutide), but this enhanced efficacy comes with marginally higher gastrointestinal side effect rates during initial months [1][2]. Patients prioritising maximum efficacy who can tolerate temporary nausea often prefer Mounjaro, whilst those seeking proven long-term safety data may opt for semaglutide-based treatments.

Cost considerations also influence treatment selection. At Cured Pharmacy, Mounjaro starts from £124.99 with transparent upfront pricing before your free consultation. Alternative GLP-1 treatments offer different price points and dosing schedules to suit varying budgets and preferences. All prescription medications require clinical assessment by our UK-registered prescribers to ensure safety and suitability.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Side effect frequencies are based on clinical trial data and individual experiences may vary. If you experience severe or persistent side effects, contact your prescriber or seek emergency medical attention immediately.